Howard Levy, M.B.B.Ch., Ph.D., M.M.M. has over 25 years of experience in the pharmaceutical industry with a focus on critical care therapeutic areas. He practiced as an intensivist with specialty board certification in Internal Medicine, Pulmonary and Intensive Care. Since 2010 he has advised public and private biotechnology and medical device companies on clinical and drug development strategy and execution. At Sangart he developed pegylated hemoglobin as an oxygen therapeutic agent and at Eli Lilly and Company he executed post-marketing clinical trials for recombinant Activated Protein C (Xigris) in severe sepsis.

Dr. Levy has served on many clinical trial committees including Data Safety Monitoring Boards, Clinical Evaluation Committees and Health Economic assessment. Dr. Levy has more than 100 peer-reviewed publications and chapters in books, and holds M.B.B.Ch and Ph.D. degrees from University of the Witwatersrand in Johannesburg, South Africa and a M.M.M. from Carnegie Mellon University’s H. John Heinz III College.